Last
Update:
September 12, 2007
* Perinatal data are
the Perinatal Data Page
** Pediatric data are in
the Pediatric Data Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
Compared hepatotoxicity of the two available non-nucleoside reverse
transcriptase inhibitors
in a
cohort of HIV-infected patients naïve to either efavirenz or nevirapine
Manfredi R., Calza L., Chiodo F.
Abstract
Therapeutic Drug Monitoring (TDM) For Nevirapine (NVP) In A Once Dosing
Regimen
(OD) In HIV Patients Who Had Interrupted Antiretroviral Therapy (TARV): 48
Weeks
Of
Follow Up
Martinelli C., Fiorelli C., Giuntini R., Leoncini F.
Abstract
Increasing nevirapine dose can overcome reduced bioavailability due to
rifampicin co-
administration
Ramachandran G., Hemanth Kumar A.K., Rajasekaran
Abstract
Results from pilot quality control program of generic antiretrovirals: content
and
dissolution analysis of generic nevirapine (HIV-NAT026).
Autar R.S., Sankote J., Mahanontharit A., et al
Abstract
Evaluation of Nevirapine Permeability and Retention in HIV-1 Cell Free and
Budded
Virions
Costa L., Aguiar R., Pereira H., Brindeiro R., Tanuri A
Abstract
NRTI
Sparing Trial (CTN 177): Antiviral and metabolic effects of nevirapine (NVP) +
lopinavir/ritonavir (LPV/r) vs. zidovudine/lamivudine (AZT/3TC) + NVP vs.
AZT/3TC + LPV/r
Harris M., Ochoa C., Allavena C., et al
Abstract
Tolerance of full dose nevirapine switch from efavirenz in HIV-infected
patient in Cambodia
Fernandez M., Laureillard D., Prak N., et al
Abstract
TB/HIV co-infected patients on rifampicin containing treatment have equivalent
ART
treatment outcomes, and concurrent use of nevirapine is not associated with
increased
hepatotoxicity
Van Cutsem G., Cohen K., Bedelu M., et al
Abstract
Risk
of liver toxicity in HCV/HIV coinfected patients with advanced chronic liver
disease
or
cirrhosis receiving nevirapine, efavirenz or lopinavir/r
Casado J., Aranzabal L., Moya J., et al
Abstract
Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in
Patients with
Human
Immunodeficiency Virus Infection: Definitive Three-Year Results of the NEFA
Study.
Martínez E., Arnaiz J.A., Podzamcer D., et
al
Abstract
6th
International Workshop on Clinical
Pharmacology
of HIV Therapy |
-
PDF POSTER
Effect of pregnancy on Nevirapine pharmacokinetics during chronic therapy
Caparelli, E
PDF
Poster
Community-based Generic Antiretroviral Therapy following
Single-dose Nevirapine or
Short-course AZT in Zimbabwe
L Zijenah, G Kadzirange, S Rusakaniko, et al
PDF
Poster
Abstract
POSTER
Clonal Analysis of Drug-resistant Mutations in Plasma
and Breast Milk following
Single-dose Nevirapine
E Lee, R Kantor, E Johnston, et al
PDF
Poster
Abstract
POSTER
Hepatotoxicity Associated with
Nevirapine Use in HIV-infected Children
M Baylor, O Ayime, M
Truffa, et al
PDF Poster
Abstract
Hepatotoxicity Associated with
Nevirapine Use in HIV-infected Children
M Baylor, O Ayime, M
Truffa, et al
Abstract
Selection of Resistance Mutations in Children
Receiving Prophylaxis with Lamivudine or
Nevirapine for the Prevention of Postnatal
Transmission of HIV
M Giuliano, C
Galluzzo, E Germinario, et al
Abstract
Comparison of Nevirapine Resistance in Women with Subtype C Compared
with Subtypes
A and D after Single-dose NVP
SH Eshleman, D Hoover, S Chen, et al
Abstract
Pharmacogenetics of Nevirapine and Hepatotoxicity:
NWCS220, an ACTG Collaborative Study
DW Haas, J Bartlett, J Andersen, et al
Abstract
Minimum Plasma Concentrations of Nevirapine and Efavirenz in Relation to
Virologic
Failure in Antiretroviral-naive Patients
F van Leth, B Kappelhoff, D Johnson, et
al
Abstract
A Comparison of Toxicity in Nevirapine- vs Protease
Inhibitor-containing HAART Regimens
in Pregnant Women
D Money, D Khoo, G MacDonald,
et al
Abstract
Controversies in the Use of Nevirapine for Prevention
of Mother-to-Child Transmission
J McIntyre
Abstract
Efficacy of Peripartum Nevirapine to Prevent Mother to Child HIV
Transmission in Women
Presenting Late for Antenatal Care in Thailand
G Jourdain, S Le Coeur, N Ngo-Giang-Huong,
et al
Abstract
Infant Zidovudine Prophylaxis and Emergence of Nevirapine Resistance
at 6 Weeks in
Perinatally HIV-infected Infants Exposed to Intra-partum or Newborn
Nevirapine
N Ngo-Giang-Huong, G Jourdain, P Tungyai,
et al
Abstract
Sensitive Drug Resistance Assays Reveal Long-term Persistence of
HIV-1 Variants with
the K103N Nevirapine-resistance Mutation in Some Women and
Infants after Single-dose
NVP: HIVNET 012
S Eshleman, D Nissley, C Claasen, et
al
Abstract
Maternal Single-dose Nevirapine
May Not Be Needed to Reduce
Mother-to-Child HIV
Transmission in the Setting of
Maternal and Infant Zidovudine
and Infant Single-dose
Nevirapine: Results of a
Randomized Clinical Trial in
Botswana
R
Shapiro, I Thior, P Gilbert, et
al
Abstract
Preliminary Findings: Incidence of Serious Adverse Events
Attributed to Nevirapine among
Women Enrolled in an Ongoing Trial Using HAART tor Prevent
Mother-to-Child HIV
Transmission
T Thomas, P Amornkul, J Mwidau,
et al
Abstract
Nevirapine Resistance and Survival
of Women Receiving HAART Subsequent
to Prevention
of Mother-to-Child Transmission: A
Population-based Stochastic Model
D
Westreich , A Van Rie, F Behets, et
al
Abstract
Association of Cord Blood Nevirapine
with Self-reported Timing of Dose
and HIV-1
Transmission in the HIV NET 012
Study
B
Jackson, T Parsons, P Musoke, et al
Abstract
Effectiveness of
Single-dose Nevirapine in a Second
Pregnancy
N Martinson, L Pumla, L
Morris, et al
Abstract
Sensitive Real-Time PCR
Quantification of 103N Resistance Mutants
following Single-dose Treatment with
Nevirapine
S Loubser, P Balfe, G
Sherman, et al
Abstract
Persistence of NNRTI-r Resistant Variants after
Single-dose Nevirapine in HIV-1 Subtype-
C-infected Women
S Palmer , V Boltz , F Maldarelli, et al
Abstract
Resistance Emerges in the Majority of
Women Provided Intrapartum Single-dose Nevirapine
J
Johnson, J F Li, L Morris, et al
Abstract
-
What is the clinical relevance of the drug
interaction between nevirapine and rifampicin?
R Autar, A Mahanontharit, T Anekthananon, et al
Abstract
-
Large Nevirapine cohort: 7% discontinuation due to
Hepatotoxicity
C Koegl, E Wolf, N Ruemmelein, et al
Abstract
-
Clinical pharmacology of nevirapine (NVP) in
HIV-positive subjects with and without
HBV/HCV co-infection
S Garazzino, L Almond, S Bonora, et al
Abstract
-
Economic model of first-line antiretroviral (ARV) strategies in ARV-naïve patients: comparing
ARV drug cost of a fixed-dose
combination (FDC) of nevirapine (NVP) to an efavirenz
(EFV) -based
regimen
in Thailand
P Keiser, R Lyu, C Donnelly, A Amend Kwasnik
Abstract
-
Week 2 - Nevirapine (NVP) plasma levels are
associated with NVP-related toxicity
E Wolf, N Ruemmelein, C Hoffmann,
et al
Abstract
-
Determination of subclinical atherosclerosis in
patients on long-term nevirapine,
efavirenz,
and
protease inhibitor-based
antiretroviral therapy by ultrasound measurement of
carotid artery
intima-media
thickness and multislice cardiac CT measurement of coronary
artery calcium
G Pierone, N Cho, J Norconk, et
al
Abstract
-
Nevirapine toxicity in the obstetrical population
when used in combination with other
antiretrovirals
A Gonzalez-Garcia, M I Fernandez, A Cotter, et al
Abstract
-
Fixed-dose combination tablets of nevirapine, lamivudine, and stavudine
P Srinarong, S Prayngam, P Chunhacha, et al
Abstract
-
Readily dispersed nevirapine for oral suspension
S Watnasirichaikul, S Panchon, P Thaunsukon, et al
Abstract
-
Pharmacokinetics of nevirapine in HIV-HCV-coinfected
patients
L Héripret, T Lavrut, J Durant, et al
Abstract
-
Effect of fluconazole on nevirapine pharmacokinetics
J Geel, J A Pitt, C J Orrell, et al
Abstract
-
Therapeutic drug monitoring (TDM) of nevirapine
(NVP) in treatment-naive patients:
18 month
results from ATHENA
KML Crommentuyn, A D R Huitema, K Brinkman, et al
Abstract
-
Cutaneous adverse drug reactions to nevirapine in a
cohort of 200 patients: clinical
spectrum and results
of treating through
hypersensitivity reactive patients
E Caumes, L Roudière, R Landman, et
al
Abstract
-
Nevirapine related toxicity in a Nigerian patient receiving a fixed dose
drug combination
pill:
considerations in an era of rapidly expanding access to antiretrovirals
(ARVs) in
resource poor nations.
A Krain, O Daniel, S Ogun, et al
Abstract
-
Plasma and intracellular levels of nevirapine in HIV
infected patients by immunoassay
S Azoulay, M C Nevers, C Creminon, et
al
Abstract
-
Tolerability and adverse events of nevirapine
containing antiretroviral drugs in Gombe,
North East Nigeria.
WE Isaac, A S Shehu, A A Ali, Y B Jibrin
Abstract
-
The Confort study: A randomised and controlled open
trial of efficacy and safety of
switching protease
inhibitor to nevirapine
in patients with undetectable viral load
M Gorgolas, JC Bernaldo de Quirós, et al
Abstract
-
Predisposition to nevirapine hypersensitivity
associated with HLA-DRB1*01 and higher
CD4+ T cell
counts
A Martin, P Cameron, D Nolan, ,
et al
Abstract
-
Increase in high-density lipoprotein cholesterol when using nevirapine
and/or efavirenz is
maintained
up to 2 years
F van Leth, D Hall, J M A Lange, P Reiss
Abstract
|
|
XV
Int AIDS Conference
